| Sharma, Priyanka |
NeoPACT, NCT03639948: Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer |
|
|
| Active, not recruiting | 2 | 120 | US | Carboplatin, Docetaxel, Pembrolizumab, Pegfilgrastim | University of Kansas Medical Center, Merck Sharp & Dohme LLC | Triple-negative Breast Cancer | 01/22 | 11/24 | | |
S2007, NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases |
|
|
| Recruiting | 2 | 44 | US | Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy | SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences | Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8 | 12/27 | 12/28 | | |
NCT02393794: Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) |
|
|
| Active, not recruiting | 1/2 | 51 | US | Romidepsin, Histone deacetylase inhibitor, Cisplatin, Platinol, Nivolumab, Opdivo | Priyanka Sharma, Celgene Corporation, Bristol-Myers Squibb | Triple-Negative Breast Cancer, Breast Cancer | 12/24 | 07/25 | | |
| Recruiting | 1 | 18 | US | Alpelisib, Piqray, Sacituzumab govitecan, Trodelvy | University of Kansas Medical Center, Novartis Pharmaceuticals, Gilead Sciences | Breast Cancer | 12/24 | 12/25 | | |
| Lin, Tara |
| Recruiting | 2a | 108 | US | BP1001 in combination with Ventoclax plus decitabine, Liposomal Grb-2, L-Grb-2, BP1001 plus decitabine | Bio-Path Holdings, Inc. | Acute Myeloid Leukemia (AML) | 12/24 | 12/24 | | |
NCT02930109: A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia |
|
|
| Completed | 1/2 | 33 | US | PTX-200, Triciribine Phosphate Monohydrate, Cytarabine, Ara-C | Prescient Therapeutics, Ltd. | Acute Leukemia | 10/23 | 03/24 | | |
|
| Terminated | 1/2 | 18 | US | Fosciclopirox, Fosciclopirox + Cytarabine | CicloMed LLC | Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | 12/23 | 12/23 | | |
NCT04402541: Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome |
|
|
| Completed | 1 | 55 | US, RoW | CB-5339, CB-5339 Tosylate | Cleave Therapeutics, Inc. | Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes | 07/23 | 07/23 | | |
| Parikh, Rahul |
NCT03762161: A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer |
|
|
| Recruiting | 2 | 22 | US | TAS 102 | Rahul Parikh, Taiho Oncology, Inc. | Bladder Cancer | 07/23 | 01/24 | | |
TESLA, NCT05638698: Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 24 | US | TG01 Vaccine, QS-21, Balstilimab | University of Kansas Medical Center, Targovax ASA | Pancreas Cancer | 12/24 | 12/25 | | |
NCI-2012-01247, NCT01684397: Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer |
|
|
| Active, not recruiting | 1/2 | 51 | US | Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Laboratory Biomarker Analysis, Pazopanib Hydrochloride, GW786034B, Votrient, Pharmacological Study | Roswell Park Cancer Institute, GlaxoSmithKline | Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer | 05/25 | 05/25 | | |
| Hepler, Kerry |
| Recruiting | 2a | 108 | US | BP1001 in combination with Ventoclax plus decitabine, Liposomal Grb-2, L-Grb-2, BP1001 plus decitabine | Bio-Path Holdings, Inc. | Acute Myeloid Leukemia (AML) | 12/24 | 12/24 | | |
| Active, not recruiting | 2 | 18 | US | Niraparib Treatment | University of Kansas Medical Center, Tesaro, Inc. | Pancreatic Cancer | 04/23 | 02/25 | | |
NCT03488667: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 40 | US | Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab | University of Kansas Medical Center, Merck Sharp & Dohme LLC | Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma | 04/24 | 04/25 | | |
TESLA, NCT05638698: Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 24 | US | TG01 Vaccine, QS-21, Balstilimab | University of Kansas Medical Center, Targovax ASA | Pancreas Cancer | 12/24 | 12/25 | | |
| Navigation, KUCC |
HOTT, NCT05659381: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer |
|
|
| Recruiting | 3 | 230 | US | Cisplatin, Platinol AQ, No treatment | GOG Foundation, GlaxoSmithKline | Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer | 08/29 | 08/34 | | |
NCT03762161: A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer |
|
|
| Recruiting | 2 | 22 | US | TAS 102 | Rahul Parikh, Taiho Oncology, Inc. | Bladder Cancer | 07/23 | 01/24 | | |
TESLA, NCT05638698: Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 24 | US | TG01 Vaccine, QS-21, Balstilimab | University of Kansas Medical Center, Targovax ASA | Pancreas Cancer | 12/24 | 12/25 | | |
BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients with Glioblastoma or Non-Small Cell Lung Cancer with EGFR Mutations |
|
|
| Recruiting | 1/2 | 200 | US | BDTX-1535 monotherapy | Black Diamond Therapeutics, Inc. | Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation | 07/25 | 06/26 | | |
